BioSpace News Archive

BostonGene and Exigent Research , an independent community oncology research network, announced the BostonGene and Exigent Genomic INsight (BEGIN) Study, designed to demonstrate the clinical benefits of using BostonGene Tumor Portrait™ test for advanced cancer patients in a community setting.

Radiaction Medical, LTD announced that it has appointed industry veteran Christopher Barys to serve as its US President and Chief Commercial Officer.

ViaDerma, Inc. is pleased to announce several new and exciting business updates for current and prospective shareholders, customers, partners, and healthcare providers.

Retrieve Medical Holdings, Inc. (RMHI), the developer of Retrieve Dx™, a real-time, cloud-based CDI (Clinical Documentation Integrity) application that improves physician documentation by alerting physicians to a patient’s comorbidities and additional diagnoses.

Humanetics Corporation (Humanetics) announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Lentechs announced the closing of a successful fundraise to further key development objectives for its investigational contact lens for patients with presbyopia.

Mahana Therapeutics announced compelling results from the analysis presented by Mythili Pathipati, M.D. of Mass General Hospital at ACG 2023 Scientific Meeting in Vancouver on October 24, 2023 demonstrating that nearly 60% of users who completed Mahana IBS in the real world setting reported clinically meaningful reduction in severity of IBS symptoms.

CytoMed Therapeutics Limited recently announced its exclusively licensed induced pluripotent stem call -based technology has been granted a patent by the China National Intellectual Property Administration.

Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years.

Glycologix, Inc. (“Glycologix”), a clinical-stage company focused on developing biopolymers for the protection and repair of soft tissues, today announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).